Literature DB >> 29128069

How Do We Use Multicolor Flow Cytometry to Detect Minimal Residual Disease in Acute Myeloid Leukemia?

Jie Xu1, Jeffrey L Jorgensen1, Sa A Wang2.   

Abstract

Multicolor flow cytometry (MFC), combined with molecular and cytogenetic studies, is the most common method for detecting minimal residual disease (MRD) in acute myeloid leukemia (AML). Studies have shown that a positive MFC MRD study after induction and/or consolidation, or before allogeneic hematopoietic stem cell transplantation, correlates with risk of relapse and inferior survival. However, there is little information on technical and analytical details. This article shares the authors' experience using MFC for AML MRD detection, including antibody panel design, data analysis, and interpretation. It summarizes diagnostic pearls and pitfalls, and provides practical information for pathologists or hematologists.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute myeloid leukemia; Minimal residual disease; Multicolor flow cytometry

Mesh：

Year:  2017        PMID： 29128069     DOI： 10.1016/j.cll.2017.07.004

Source DB:  PubMed          Journal:  Clin Lab Med        ISSN： 0272-2712            Impact factor:   1.935


  14 in total

1.  Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial.

Authors:  Tapan M Kadia; Jorge Cortes; Farhad Ravandi; Elias Jabbour; Marina Konopleva; Christopher B Benton; Jan Burger; Koji Sasaki; Gautam Borthakur; Courtney D DiNardo; Naveen Pemmaraju; Naval Daver; Alessandra Ferrajoli; Xuemei Wang; Keyur Patel; Jeffrey L Jorgensen; Sa Wang; Susan O'Brien; Sherry Pierce; Carla Tuttle; Zeev Estrov; Srdan Verstovsek; Guillermo Garcia-Manero; Hagop Kantarjian
Journal:  Lancet Haematol       Date:  2018-08-13       Impact factor: 18.959

2.  Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias.

Authors:  Abhishek Maiti; Miguel J Franquiz; Farhad Ravandi; Jorge E Cortes; Elias J Jabbour; Koji Sasaki; Kayleigh Marx; Naval G Daver; Tapan M Kadia; Marina Y Konopleva; Lucia Masarova; Gautam Borthakur; Courtney D DiNardo; Kiran Naqvi; Sherry Pierce; Hagop M Kantarjian; Nicholas J Short
Journal:  Acta Haematol       Date:  2020-04-14       Impact factor: 2.195

Review 3.  Flow Cytometric Minimal Residual Disease Analysis in Acute Leukemia: Current Status.

Authors:  Pulkit Rastogi; Man Updesh Singh Sachdeva
Journal:  Indian J Hematol Blood Transfus       Date:  2019-04-02       Impact factor: 0.900

4.  10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.

Authors:  Courtney D DiNardo; Abhishek Maiti; Caitlin R Rausch; Naveen Pemmaraju; Kiran Naqvi; Naval G Daver; Tapan M Kadia; Gautam Borthakur; Maro Ohanian; Yesid Alvarado; Ghayas C Issa; Guillermo Montalban-Bravo; Nicholas J Short; Musa Yilmaz; Prithviraj Bose; Elias J Jabbour; Koichi Takahashi; Jan A Burger; Guillermo Garcia-Manero; Nitin Jain; Steven M Kornblau; Philip A Thompson; Zeev Estrov; Lucia Masarova; Koji Sasaki; Srdan Verstovsek; Alessandra Ferrajoli; William G Weirda; Sa A Wang; Sergej Konoplev; Zhining Chen; Sherry A Pierce; Jing Ning; Wei Qiao; Farhad Ravandi; Michael Andreeff; John S Welch; Hagop M Kantarjian; Marina Y Konopleva
Journal:  Lancet Haematol       Date:  2020-09-05       Impact factor: 18.959

5.  Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia.

Authors:  Abhishek Maiti; Courtney D DiNardo; Sa A Wang; Jeffrey Jorgensen; Tapan M Kadia; Naval G Daver; Nicholas J Short; Musa Yilmaz; Naveen Pemmaraju; Gautam Borthakur; Prithviraj Bose; Ghayas C Issa; Alessandra Ferrajoli; Elias J Jabbour; Nitin Jain; Guillermo Garcia-Manero; Maro Ohanian; Koichi Takahashi; Guillermo Montalban-Bravo; Lucia Masarova; Jan A Burger; Philip A Thompson; Srdan Verstovsek; Koji Sasaki; Michael Andreeff; Caitlin R Rausch; Kathryn S Montalbano; Sherry Pierce; Wei Qiao; Jing Ning; Hagop M Kantarjian; Marina Y Konopleva; Farhad Ravandi
Journal:  Blood Adv       Date:  2021-04-13

6.  Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia.

Authors:  Chi Young Ok; Sanam Loghavi; Dawen Sui; Peng Wei; Rashmi Kanagal-Shamanna; C Cameron Yin; Zhuang Zuo; Mark J Routbort; Guilin Tang; Zhenya Tang; Jeffrey L Jorgensen; Rajyalakshmi Luthra; Farhad Ravandi; Hagop M Kantarjian; Courtney D DiNardo; L Jeffrey Medeiros; Sa A Wang; Keyur P Patel
Journal:  Haematologica       Date:  2018-08-31       Impact factor: 11.047

7.  Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study.

Authors:  Patrick K Reville; Hagop M Kantarjian; Farhad Ravandi; Elias Jabbour; Courtney D DiNardo; Naval Daver; Naveen Pemmaraju; Maro Ohanian; Yesid Alvarado; Lianchun Xiao; Gheath Alatrash; Sanam Loghavi; Caitlin R Rausch; Gautam Borthakur; Marina Konopleva; Jorge Cortes; Tapan M Kadia
Journal:  Blood Cancer J       Date:  2021-03-17       Impact factor: 11.037

8.  Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia.

Authors:  Sanam Loghavi; Courtney D DiNardo; Ken Furudate; Koichi Takahashi; Tomoyuki Tanaka; Nicholas J Short; Tapan Kadia; Marina Konopleva; Rashmi Kanagal-Shamanna; Noushin R Farnoud; Sherry Pierce; Joseph D Khoury; Jeffrey L Jorgensen; Keyur P Patel; Naval Daver; Musa Yilmaz; L Jeffrey Medeiros; Hagop Kantarjian; Farhad Ravandi; Sa A Wang
Journal:  Br J Haematol       Date:  2021-02-22       Impact factor: 6.998

9.  Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.

Authors:  Courtney D DiNardo; Curtis A Lachowiez; Koichi Takahashi; Sanam Loghavi; Lianchun Xiao; Tapan Kadia; Naval Daver; Maria Adeoti; Nicholas J Short; Koji Sasaki; Sa Wang; Gautam Borthakur; Ghayas Issa; Abhishek Maiti; Yesid Alvarado; Naveen Pemmaraju; Guillermo Montalban Bravo; Lucia Masarova; Musa Yilmaz; Nitin Jain; Michael Andreeff; Elias Jabbour; Guillermo Garcia-Manero; Steven Kornblau; Farhad Ravandi; Marina Y Konopleva; Hagop M Kantarjian
Journal:  J Clin Oncol       Date:  2021-05-27       Impact factor: 50.717

10.  Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial.

Authors:  Tapan M Kadia; Patrick K Reville; Gautam Borthakur; Musa Yilmaz; Steven Kornblau; Yesid Alvarado; Courtney D Dinardo; Naval Daver; Nitin Jain; Naveen Pemmaraju; Nicholas Short; Sa A Wang; Rebecca S S Tidwell; Rabiul Islam; Marina Konopleva; Guillermo Garcia-Manero; Farhad Ravandi; Hagop M Kantarjian
Journal:  Lancet Haematol       Date:  2021-08       Impact factor: 30.153
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.